145 related articles for article (PubMed ID: 17000222)
21. Competing risk analysis of cause-specific mortality in patients with an implantable cardioverter-defibrillator: The EVADEF cohort study.
Marijon E; Trinquart L; Otmani A; Waintraub X; Kacet S; Clémenty J; Chatellier G; Le Heuzey JY;
Am Heart J; 2009 Feb; 157(2):391-397.e1. PubMed ID: 19185651
[TBL] [Abstract][Full Text] [Related]
22. Use of beta-blockers in patients with an implantable cardioverter defibrillator.
LaPointe NM; Stafford JA; Pappas PA; Al-Khatib SM; Anstrom KJ
Ann Pharmacother; 2009 Jul; 43(7):1189-96. PubMed ID: 19567655
[TBL] [Abstract][Full Text] [Related]
23. Sudden death prior to pediatric heart transplantation: would implantable defibrillators improve outcome?
Rhee EK; Canter CE; Basile S; Webber SA; Naftel DC
J Heart Lung Transplant; 2007 May; 26(5):447-52. PubMed ID: 17449412
[TBL] [Abstract][Full Text] [Related]
24. Moderate exercise training improves functional capacity, quality of life, and endothelium-dependent vasodilation in chronic heart failure patients with implantable cardioverter defibrillators and cardiac resynchronization therapy.
Belardinelli R; Capestro F; Misiani A; Scipione P; Georgiou D
Eur J Cardiovasc Prev Rehabil; 2006 Oct; 13(5):818-25. PubMed ID: 17001224
[TBL] [Abstract][Full Text] [Related]
25. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy.
Cuoco FA; Spencer WH; Fernandes VL; Nielsen CD; Nagueh S; Sturdivant JL; Leman RB; Wharton JM; Gold MR
J Am Coll Cardiol; 2008 Nov; 52(21):1718-23. PubMed ID: 19007692
[TBL] [Abstract][Full Text] [Related]
26. Impact of the main implantable cardioverter-defibrillator trials in clinical practice: data from the Italian ICD Registry for the years 2005-07.
Proclemer A; Ghidina M; Gregori D; Facchin D; Rebellato L; Fioretti P; Brignole M
Europace; 2009 Apr; 11(4):465-75. PubMed ID: 19136490
[TBL] [Abstract][Full Text] [Related]
27. Implantable cardioverter defibrillators and quality of life: results from the defibrillators in nonischemic cardiomyopathy treatment evaluation study.
Passman R; Subacius H; Ruo B; Schaechter A; Howard A; Sears SF; Kadish A
Arch Intern Med; 2007 Nov; 167(20):2226-32. PubMed ID: 17998496
[TBL] [Abstract][Full Text] [Related]
28. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy.
McLeod CJ; Ommen SR; Ackerman MJ; Weivoda PL; Shen WK; Dearani JA; Schaff HV; Tajik AJ; Gersh BJ
Eur Heart J; 2007 Nov; 28(21):2583-8. PubMed ID: 17483110
[TBL] [Abstract][Full Text] [Related]
29. Implantable cardioverter defibrillators and Chagas' disease: results of the ICD Registry Latin America.
Muratore CA; Batista Sa LA; Chiale PA; Eloy R; Tentori MC; Escudero J; Lima AM; Medina LE; Garillo R; Maloney J
Europace; 2009 Feb; 11(2):164-8. PubMed ID: 19056745
[TBL] [Abstract][Full Text] [Related]
30. Deactivating the implantable cardioverter-defibrillator: a biofixture analysis.
Paola FA; Walker RM
South Med J; 2000 Jan; 93(1):20-3. PubMed ID: 10653059
[TBL] [Abstract][Full Text] [Related]
31. Indications for ICD and cardiac resynchronization therapy for prevention of sudden cardiac death.
Das M
Expert Rev Cardiovasc Ther; 2009 Feb; 7(2):181-95. PubMed ID: 19210214
[TBL] [Abstract][Full Text] [Related]
32. Rates and predictors of appropriate implantable cardioverter-defibrillator therapy delivery: results from the EVADEF cohort study.
Otmani A; Trinquart L; Marijon E; Lavergne T; Waintraub X; Lepillier A; Chatellier G; Le Heuzey JY;
Am Heart J; 2009 Aug; 158(2):230-237.e1. PubMed ID: 19619699
[TBL] [Abstract][Full Text] [Related]
33. Implantable cardioverter-defibrillator implantation as a bridge to cardiac transplantation.
Da Rosa MR; Sapp JL; Howlett JG; Falkenham A; Légaré JF
J Heart Lung Transplant; 2007 Dec; 26(12):1336-9. PubMed ID: 18096488
[TBL] [Abstract][Full Text] [Related]
34. Outcome after implantation of cardioverter defibrillator [corrected] in patients with Brugada syndrome: a multicenter Israeli study (ISRABRU).
Rosso R; Glick A; Glikson M; Wagshal A; Swissa M; Rosenhek S; Shetboun I; Khalamizer V; Fuchs T; Boulos M; Geist M; Strasberg B; Ilan M; Belhassen B;
Isr Med Assoc J; 2008 Jun; 10(6):435-9. PubMed ID: 18669142
[TBL] [Abstract][Full Text] [Related]
35. Microvolt T-wave alternans identifies patients with ischemic cardiomyopathy who benefit from implantable cardioverter-defibrillator therapy.
Chow T; Kereiakes DJ; Bartone C; Booth T; Schloss EJ; Waller T; Chung E; Menon S; Nallamothu BK; Chan PS
J Am Coll Cardiol; 2007 Jan; 49(1):50-8. PubMed ID: 17207722
[TBL] [Abstract][Full Text] [Related]
36. [Electrical storm in patients with implantable cardioverter-defibrillator].
Bárzaga FJ; Clavijo PC; Sánchez MD; Hevia JC; Molina RZ; Pérez MA; Leza JB; Rodríguez YF; Balea FD
Arch Cardiol Mex; 2008; 78(1):68-78. PubMed ID: 18581715
[TBL] [Abstract][Full Text] [Related]
37. Depression and anxiety status of patients with implantable cardioverter defibrillator and precipitating factors.
Bilge AK; Ozben B; Demircan S; Cinar M; Yilmaz E; Adalet K
Pacing Clin Electrophysiol; 2006 Jun; 29(6):619-26. PubMed ID: 16784428
[TBL] [Abstract][Full Text] [Related]
38. Role of amiodarone or implantable cardioverter/defibrillator in patients with atrial fibrillation and heart failure.
Singh SN; Poole J; Anderson J; Hellkamp AS; Karasik P; Mark DB; Lee KL; Bardy GH;
Am Heart J; 2006 Nov; 152(5):974.e7-11. PubMed ID: 17070171
[TBL] [Abstract][Full Text] [Related]
39. A comparison of outcomes for patients receiving implantable cardioverter defibrillators for primary vs secondary-prevention.
Giedrimas A; Giedrimiene D; Guertin D; White CM; Clyne CA; Kluger J
Conn Med; 2008; 72(6):329-33. PubMed ID: 18610705
[TBL] [Abstract][Full Text] [Related]
40. Implantable cardioverter defibrillators and their role in heart failure progression.
Cevik C; Perez-Verdia A; Nugent K
Europace; 2009 Jun; 11(6):710-5. PubMed ID: 19357142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
